TXG — 10x Genomics, Inc.

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $166 million, representing a 1% year-over-year growth and exceeding guidance.
• Full Year 2025 Revenue: $599 million (excluding $44 million from patent litigation settlements).
• Consumables Revenue: Up 6% in Q4, with single cell consumables growing 3%.
• Instrument Revenue: Declined 36% in Q4, with Chromium instruments down 44% and spatial instruments down 30%.
• Gross Margin: 68% for 2025, up from 67% in 2024.
• Cash Position: Ended the year with $523 million in cash, up $130 million from 2024.

2. Strategic Updates and Business Highlights

• Product Innovations: Launched FLEX APEX, a next-generation single cell assay, which has become the most popular single cell assay by volume in Q4. Introduced new capabilities in spatial analysis with Visium HD 3' and Xenium RNA and protein.
• Market Trends: Strong demand for single cell and spatial technologies, particularly in translational research and AI applications. The company is focusing on partnerships to support large-scale studies and clinical applications.
• Translational Research: Significant growth potential identified in biopharma and clinical diagnostics, with ongoing collaborations to generate clinical evidence.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $600 million and $625 million, indicating 0% to 4% growth over 2025.
• Market Conditions: Anticipated continued pressure on capital equipment purchases, but a more stable funding environment is expected compared to 2025.
• Q1 2026 Outlook: Expected to represent a larger percentage of full-year revenue due to orders received late in Q4 2025.

4. Bad News, Challenges, or Points of Concern

• Subdued Customer Spending: Ongoing uncertainty in research funding dynamics continues to impact purchasing decisions, particularly in the U.S. academic and government sectors.
• Instrument Revenue Decline: Significant drop in instrument sales due to constrained capital spending, which is expected to persist in 2026.
• Competitive Pressures: While 10x Genomics maintains a strong position, there is ongoing competition in the market, particularly in spatial analysis, with a noted shift in customer preference towards Xenium over Visium.

5. Notable Q&A Insights

• Customer Sentiment: The operating environment remains cautious, with funding uncertainties impacting customer behavior. However, there are signs of gradual improvement compared to 2025.
• AI Applications: Demand for AI-driven projects is expected to grow, with FLEX APEX positioned well for these applications.
• Clinical Applications: The company is pursuing a hybrid strategy for clinical deployment, focusing on generating clinical evidence and establishing a CLIA lab to support diagnostics.
• Translational Research Growth: There is a strong belief that biopharma adoption could significantly increase, with the potential for half of revenue to come from this sector in the future.

Overall, while 10x Genomics faced challenges in 2025, particularly in instrument sales and funding dynamics, the company is optimistic about its product innovations, strategic partnerships, and potential growth in translational research and clinical applications moving into 2026.